公开(公告)号：US20240355476A1

公开(公告)日：2024-10-24

申请号：US18761410

申请日：2024-07-02

申请人： THE UNIVERSITY OF CHICAGO

发明人： Suzanne D. CONZEN ,  Lei HUANG ,  Maria KOCHERGINSKY ,  Diana SZYMANSKI

IPC分类号： G16H50/20 ,  C12Q1/6809 ,  C12Q1/6827 ,  C12Q1/6837 ,  C12Q1/6886 ,  G16H50/30

CPC分类号： G16H50/20 ,  C12Q1/6809 ,  C12Q1/6827 ,  C12Q1/6837 ,  C12Q1/6886 ,  G16H50/30 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158

摘要： Embodiments are directed to kits and methods of treating a breast cancer patient with a glucocorticoid receptor antagonist with or without an anticancer agent or compound after the patient has been determined to be susceptible to treatment with the glucocorticoid receptor antagonist.

公开(公告)号：US20240352120A1

公开(公告)日：2024-10-24

申请号：US18442934

申请日：2024-02-15

申请人： Mayo Foundation for Medical Education and Research

发明人： Lieping Chen ,  Scott E. Strome ,  Eugene D. Kwon, IV

IPC分类号： C07K16/28 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  C07K16/30 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/569 ,  G01N33/574

CPC分类号： C07K16/2803 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  C07K16/2827 ,  C07K16/30 ,  C12N15/113 ,  C12N15/1138 ,  C12Q1/6886 ,  G01N33/5088 ,  G01N33/5091 ,  G01N33/56972 ,  G01N33/57407 ,  G01N33/57438 ,  G01N33/57484 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

公开(公告)号：US20240350460A1

公开(公告)日：2024-10-24

申请号：US18685925

申请日：2022-08-18

申请人： NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD

发明人： Yufeng SHI ,  Wenjiang MA

IPC分类号： A61K31/422 ,  A61K31/345 ,  A61P35/00 ,  C12Q1/6886

CPC分类号： A61K31/422 ,  A61K31/345 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/154 ,  C12Q2600/158

摘要： The present invention relates to an application of a hydrazide compound in tumor treatment, and, in particular, the present invention provides a use of a compound represented by formula I, an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, being used for the preparation of a composition or formulation, said composition or formulation being used for the prevention and/or treatment of tumors. The compound of the present invention has significant and exceptional therapeutic effects on tumors having low or no expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, high methylation level at the NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in the NNMT gene region.

公开(公告)号：US12123058B2

公开(公告)日：2024-10-22

申请号：US16963948

申请日：2019-01-25

申请人： SORBONNE UNIVERSITE ,  CTRE RECHERCHE PATHOLOGIES PROSTATIQUES ,  LIGUE NATIONALE CONTRE LE CANCER ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE TOURS ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS

发明人： Olivier Cussenot ,  Aurélie Kamoun ,  Aurélien De Reynies ,  Géraldine Cancel-Tassin ,  Gaëlle Fromont-Hankard

IPC分类号： C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158

摘要： A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.

公开(公告)号：US12120998B2

公开(公告)日：2024-10-22

申请号：US17250303

申请日：2019-07-02

申请人： NEW WEST GENETICS INC.

发明人： Richard S. Fletcher

IPC分类号： A01H6/28 ,  A01H1/02 ,  A01H1/04 ,  A01H5/02 ,  C12Q1/6895

CPC分类号： A01H6/28 ,  A01H1/022 ,  A01H1/045 ,  A01H5/02 ,  C12Q1/6895 ,  C12Q2600/13 ,  C12Q2600/158

摘要： According to the invention, there is provided a novel hemp Cannabis cultivar which produces a skewed ratio of female plants. This invention thus relates to the seeds of hemp Cannabis cultivar of the invention, to the plants of hemp Cannabis cultivar of the invention, to plant parts of hemp Cannabis cultivar of the invention, to methods for producing a Cannabis cultivar by crossing the hemp Cannabis cultivar of the invention with another Cannabis cultivar, and to methods for producing a Cannabis cultivar containing in its genetic material one or more backcross conversion traits or transgenes and to the backcross conversion Cannabis plants and plant parts produced by those methods.

公开(公告)号：US20240344138A1

公开(公告)日：2024-10-17

申请号：US18552410

申请日：2022-03-24

申请人： Feng Biosciences, Inc

发明人： Laura E. BENJAMIN ,  Kristen STRAND-TIBBITTS ,  Rafael ROSENGARTEN ,  Miha ŠTAJDOHAR ,  Robert CVITKOVIC

IPC分类号： C12Q1/6886 ,  A61K45/00 ,  G16B25/10 ,  G16H50/20

CPC分类号： C12Q1/6886 ,  A61K45/00 ,  G16B25/10 ,  G16H50/20 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

摘要： The disclosure provides methods to categorize cancers and cancer patients using a classifier, TME Panel-1, which stratifies patients and cancers according to tumor microenvironments. Treatment decisions are then guided by the presence/absence of a particular TME phenotype class. Also provided are methods for treating a subject, e.g., a human subject, afflicted with gastric cancer, breast cancer, prostate cancer, liver cancer, carcinoma of head and neck, melanoma, colorectal cancer, or ovarian cancer comprising administering a particular therapy depending on the classification of the cancer's TME according to the TME Panel-1 classifier. Also provided are personalized treatments that can be administered to patients depending on the TME Panel-1 classification of a particular type of cancer, e.g., left or right colorectal cancer or dMMR colorectal cancer.

公开(公告)号：US20240344136A1

公开(公告)日：2024-10-17

申请号：US18516168

申请日：2023-11-21

申请人： The Johns Hopkins University ,  University of Torino

发明人： Victor E. Velculsecu ,  Eniko Papp ,  Vilmos Adleff ,  Andrea Bertotti ,  Livio Trusolino

IPC分类号： C12Q1/6886 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  A61K39/395 ,  A61P35/00 ,  C07K16/2863 ,  C12Q1/68 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

摘要： Recent large-scale analyses have demonstrated that the genomic landscape of human cancer is complex and variable among individuals of the same tumor type. Such underlying genetic differences may in part be responsible for the varying therapeutic responses observed in cancer patients. To examine the effect of somatic genetic changes in colorectal cancer on sensitivity to a common targeted therapy, we performed complete exome sequence and copy number analyses of 129 tumors that were KRAS wild-type and analyzed their response to anti-EGFR antibody blockade in patient-derived tumorgraft models. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumors with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumorgraft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluate response to targeted therapies in human cancer, highlight additional mechanisms of responsiveness to anti-EGFR therapies, and provide additional avenues for intervention in the management of colorectal cancer.

公开(公告)号：US20240344126A1

公开(公告)日：2024-10-17

申请号：US18513534

申请日：2023-11-18

申请人： Phenomune, LLC

发明人： Henry P. Barham

IPC分类号： C12Q1/6876 ,  G01N21/77 ,  G01N33/50 ,  G01N33/566

CPC分类号： C12Q1/6876 ,  G01N33/5041 ,  G01N33/566 ,  C12Q2600/158 ,  G01N2021/7769 ,  G01N2333/726

摘要： A method of measuring phenotypic expression of T2Rs and/or TIRs for a subject to predict taste preferences for wines may include stimulating T2Rs and/or TIRs of a subject with agonists and detecting products released as a result of stimulation of the T2Rs and/or T1Rs. A method may include recording discerned levels of taste perception after stimulation with agonists and correlating the discerned level to phenotypic expression, which may be used to predict taste preferences for wine profiles. A method may include calculating wine bin scores for predicted wine preferences, from phenotypic expression of T2Rs and/or T1Rs, obtaining taste preference information, and determining the subject's taste preference scores for wines administered to the subject.

公开(公告)号：US20240343804A1

公开(公告)日：2024-10-17

申请号：US18294747

申请日：2022-08-17

申请人： Mayo Foundation for Medical Education and Research

发明人： Aaron S. Mansfield ,  Mitesh J. Borad ,  George Vasmatzis ,  Farhad Kosari

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C12Q1/6886

CPC分类号： C07K16/2818 ,  A61P35/00 ,  C12Q1/6886 ,  A61K2039/505 ,  C12Q2600/158

摘要： This document provides methods and materials for assessing and/or treating mammals (e.g., humans) having mesothelioma (e.g., mesothelioma with a high junction burden). For example, methods and materials that can be used to determine whether or not a mammal having mesothelioma is likely to respond to a particular cancer treatment (e.g., immunotherapy with one or more immune checkpoint inhibitors) are provided. Methods and materials for treating a mammal (e.g., a human) having mesothelioma (e.g., mesothelioma with a high junction burden) where the treatment is selected based, at least in part, on whether or not the mammal is likely to respond to a particular cancer treatment (e.g., immunotherapy with one or more immune checkpoint inhibitors) also are provided.

公开(公告)号：US20240336980A1

公开(公告)日：2024-10-10

申请号：US18747178

申请日：2024-06-18

申请人： Natera, Inc.

发明人： Joshua Babiarz ,  Tudor Pompiliu Constantin ,  Lane A. Eubank ,  George Gemelos ,  Matthew Micah Hill ,  Huseyin Eser Kirkizlar ,  Matthew Rabinowitz ,  Onur Sakarya ,  Styrmir Sigurjonsson ,  Bernhard Zimmermann

IPC分类号： C12Q1/6886 ,  C12Q1/6869 ,  G06N7/01 ,  G06N20/00 ,  G16B15/00 ,  G16B20/00 ,  G16B20/10 ,  G16B20/20 ,  G16B25/00 ,  G16B25/20 ,  G16B40/00 ,  G16B40/20 ,  G16H10/40 ,  G16H50/20 ,  G16Z99/00

CPC分类号： C12Q1/6886 ,  C12Q1/6869 ,  G06N7/01 ,  G06N20/00 ,  G16B15/00 ,  G16B20/00 ,  G16B20/10 ,  G16B20/20 ,  G16B25/00 ,  G16B40/00 ,  G16B40/20 ,  G16H10/40 ,  G16H50/20 ,  G16Z99/00 ,  C12Q2539/10 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/172 ,  G16B25/20

摘要： The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.